Unitree shares fall 45% from their debut peak, wiping out $30bn

Unitree’s shares are down ~45% from their peak on the first day of trading in Shanghai, shifting the narrative from “national success” to concerns about how China prices new listings. After three straight sessions of declines, the stock steadied on Tuesday, with Reuters noting investors are now focused on the valuation of the Hangzhou humanoid company.

Analysis

The important signal is not the drawdown itself but the market’s rejection of scarcity pricing for a pre-profit China robotics name. That tends to spill over to every adjacent “future of automation” listing, because public comps are what venture investors, bankers, and secondary sellers use to justify the next round. The immediate losers are late-stage backers and any underwriters hoping to seed a pipeline of similar deals; the longer-term loser is the financing environment for Chinese humanoid/embodied-AI startups that need repeated capital before revenue maturity.

Over the next 1-3 months, the key catalyst is whether the company can prove conversion from demos into recurring orders and gross margin leverage. If it cannot, bounces are likely technical rather than fundamental, especially around any insider lockup/supply overhangs or when broader China risk appetite cools. That creates a second-order benefit for profitable industrial automation players: capital shifts away from story stocks toward names with installed base, service revenue, and observable cash generation.

Contrarianly, this may be more of a normalization than a business failure if the first-day tape was distorted by retail scarcity and speculative flow. The bearish thesis is falsified by a credible commercial orders update, stable post-IPO ownership behavior despite weak momentum, or margin disclosure showing the unit economics improve with scale. Without that, the chart is telling us the market is demanding cash flow, not prototypes.

Key Decisions for Investors

• No direct long here; treat this as a watchlist item and wait for the first earnings/order update before touching the name. If revenue conversion and gross margin do not inflect, the risk/reward remains unfavorable.
• Expression for 1-3 months: long BOTZ or ROBO against short ASHR or CNYA to isolate global robotics adoption from China speculative-tech valuation compression. Falsify if China small-cap/tech leadership reasserts on improving policy or liquidity.
• Avoid adding exposure to Chinese pre-profit humanoid/AI hardware peers until the public-market comp stabilizes. A further 10-15% downside is plausible if lockup-related supply hits into weak momentum.
• For private-market or crossover portfolios, haircut comparable valuation marks in the China embodied-AI stack and defer secondary purchases until a real-order print resets the multiple.